75783-45-8

Usage

Uses

Used in Organic Synthesis:
5-O-(tert-Butyldiphenylsilyl)-1,2-O-isopropylidene-alpha-D-erythro-pentofuranos-3-ulose is used as a building block in organic synthesis for its unique reactivity and functionality. It allows for the creation of a wide range of complex organic molecules that can be utilized in various applications.
Used in Chemical Reactions:
In the field of chemical reactions, 5-O-(tert-Butyldiphenylsilyl)-1,2-O-isopropylidene-alpha-D-erythro-pentofuranos-3-ulose serves as a key intermediate. Its specific modifications enable it to participate in reactions that can lead to the development of new compounds with potential applications in various industries.
Used in Research and Development:
5-O-(tert-Butyldiphenylsilyl)-1,2-O-isopropylidene-alpha-D-erythro-pentofuranos-3-ulose is also used in research and development settings. Its complex structure and reactivity make it a valuable tool for exploring new chemical pathways and understanding the behavior of similar compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-O-(tert-Butyldiphenylsilyl)-1,2-O-isopropylidene-alpha-D-erythro-pentofuranos-3-ulose may be used as a starting material for the synthesis of potential drug candidates. Its unique properties could contribute to the development of new medications with novel mechanisms of action.
Used in Biochemical Applications:
5-O-(tert-Butyldiphenylsilyl)-1,2-O-isopropylidene-alpha-D-erythro-pentofuranos-3-ulose can be employed in biochemical applications, where its carbohydrate derivative nature and modified groups may interact with biological systems in ways that could be harnessed for various purposes, such as the development of diagnostic tools or therapeutic agents.

Upstream product

• 20031-21-4 1,2-O-isopropylidene-α-D-xylose 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 58-86-6 D-xylose 
• 87-72-9 D-Xylose 
• 67-64-1 acetone 
• 532-20-7 D-xylofuranose 
• 266306-54-1 (E/Z)-5-O-(tert-Butyldiphenylsilyl)-3-deoxy-3-hydroxyimino-1,2-O-isopropylidene-α-D-erythro-pentofuranose 
• 20881-04-3 1,2:3,5-di-O-isopropylidene-D-xylofuranose 
• 1165952-91-9 cyclohexa-1,3-diene 
• 217438-62-5 5-O-(tert-butyldiphenylsilyl)-3-chloro-3-deoxy-1,2-O-isopropylidene-3-C-nitroso-α-D-xylofuranose 
• 114861-14-2 1,2-O-isopropylidene-5-O-(t-butyldiphenylsilyl)-α-D-xylofuranose 

Downstream Products

• 179236-11-4 tert-butyl-(2,2-dimethyl-6-methylene-tetrahydro-furo[2,3-d][1,3]dioxol-5-ylmethoxy)-diphenyl-silane 
• 266306-54-1 (E/Z)-5-O-(tert-Butyldiphenylsilyl)-3-deoxy-3-hydroxyimino-1,2-O-isopropylidene-α-D-erythro-pentofuranose 
• 765942-29-8 (2S,3S,4R)-3,5-O-dibenzyloxy-1,2,4-O-tri-tert-butyldimethylsilyloxypentane 
• 765942-31-2 (2R,3R,4S)-1-[Bis-(4-methoxy-phenyl)-phenyl-methoxy]-2,4,5-tris-(tert-butyl-dimethyl-silanyloxy)-pentan-3-ol 
• 37077-81-9 1,2-isopropylidene-α-D-ribofuranose 
• 16054-78-7 (2S,3S,4R)-3,5-O-dibenzyloxy-1,2,4-pentanetriol 
• 55735-86-9 3,5-O-dibenzyloxy-1,2-O-isorpopylidene-α-D-ribofuranose 
• 69827-90-3 5-O-benzoyl-3-C-benzoyloxymethyl-3-deoxy-1,2-O-isopropylidene-α-D-ribo-pentofuranose 
• 75772-03-1 [(3aR,5S,6R,6aR)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-6-yl]-methanol 
• 159312-42-2 (3aR,5R,6R,6aR)-6-Benzyloxy-5-benzyloxymethyl-2,2,6-trimethyl-tetrahydro-furo[2,3-d][1,3]dioxole 
• 130469-49-7 5-O-benzoyl-3-deoxy-3-<(benzoyloxy)methyl>-1,2-di-O-acetyl-β-D-ribofuranose 

Relevant academic research and scientific papers

Method for synthesizing 3'-methoxy guanosine

The invention discloses a synthesis method of 3'-methoxy guanosine, belonging to the technical field of medicines. The method comprises the following steps: with 1,2-O-isopropylidene-alpha-D-xylofuranose I as an initial raw material, selectively protectin

PRMT5 INHIBITORS

The present invention provides a compound of formula (I) Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, are PRMT5 inhibitors. Also provided are methods of making compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

NICOTINAMIDE ADENINE DINUCLEOTIDE ANALOGUES

Provided herein are nicotinamide adenine dinucleotide analogues, compositions comprising such compounds, and methods of using such analogues and compositions.

ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF

The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

Synthesis of Ribonucleosidic Dimers with an Amide Linkage from D-Xylose

An original and efficient stereocontrolled synthesis of ribonucleosidic homo- and heterodimers has been achieved from inexpensive d-xylose. This successful strategy involved the sequential introduction of nucleobases, using two stereocontrolled N-glycosidation reactions, from a common two-furanoside amide-linked scaffold offering the possibility of obtaining any given base sequence. The pertinence of this approach is illustrated through the preparation of the homodimers UU-34 and TT-35 in 18 steps with an excellent overall yield of more than 10% from d-xylose, while the heterodimer route led to UT-39 in 19 steps with around 10% overall yield.

3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either al

A visualizable chain-terminating inhibitor of glycosaminoglycan biosynthesis in developing zebrafish

Heparan sulfate (HS) and chondroitin sulfate (CS) glycosaminoglycans (GAG) are proteoglycan-associated polysaccharides with essential functions in animals. They have been studied extensively by genetic manipulation of biosynthetic enzymes, but chemical to

Independent generation and characterization of a C2′-oxidized abasic site in chemically synthesized oligonucleotides

Abasic lesions, which are formed endogenously and as a consequence of exogenous agents, are lethal and mutagenic. Hydrogen atom abstraction from C2′ in DNA under aerobic conditions produces an oxidized abasic lesion (C2-AP), along with other forms of DNA

Synthesis of novel D- and L-3′-deoxy-3′-C-Hydroxymethyl nucleoside with exocyclic methylene as potential ribonucleotide reductase inhibitor

D- and L-3′-Deoxy-3′-C-hydroxymethyl thymidine substituted with exocyclic methylene at 2′-position were synthesized, starting from D- and L-xylose as potential ribonucleotide reductase inhibitor, respectively, but they were found to be inactive against several tumor cell lines.